Astellas received fast-track status from the FDA for gilteritinib as a treatment for patients with relapsed or refractory acute myeloid leukemia.
Astellas' acute myeloid leukemia drug fast-tracked by FDA
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.